ASP 6858

Drug Profile

ASP 6858

Alternative Names: ASP6858

Latest Information Update: 27 May 2016

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Renal failure

Most Recent Events

  • 11 May 2016 Discontinued - Phase-I for Renal failure (In volunteers) in United Kingdom (PO)
  • 06 Oct 2015 Astellas Pharma restarts enrolment in a phase I trial in Healthy volunteers in United Kingdom (NCT02359032)
  • 06 Aug 2015 Astellas Pharma suspends a phase I trial in Healthy volunteers in United Kingdom due to operational reasons (PO) (NCT02359032)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top